Researchers at the Francis Crick Institute and the University of Western Australia have developed a new imaging method to see where antibiotics have reached bacteria within tissues. The method could be used to help develop more effective antibiotic treatments, reducing the risk of antibiotic resistance.
During bacterial infections like tuberculosis, bacteria enter human cells, which poses a challenge for treatment, as antibiotics must reach and enter all infected cells in order to be effective. If researchers could select for or develop more effective antibiotics based on where they reach, this may reduce the length of treatment needed, which in turn could reduce the risk of antibiotic resistance developing.
In their study, published in PLoS Biology the researchers developed a new imaging method to see where in infected tissues and in cells an antibiotic given to treat tuberculosis reaches the bacteria. The scientists are continuing to work on the method, adapting it for other types of antibiotic and to image multiple antibiotics at the same time.
Max Gutierrez, author and group leader of the Host-Pathogen Interactions in Tuberculosis Laboratory at the Crick, says: "In the case of tuberculosis, people need to be treated with at least three different antibiotics over six months. We don't yet fully understand why this extended treatment is needed. We hope that being able to more clearly see where antibiotics are going, will help us better understand this process and find ways to improve it."
To develop the imaging method, called CLEIMiT,* the researcher analysed lung tissue from mice infected with tuberculosis and treated with the antibiotic bedaquiline.
They combined a variety of imaging methods, including confocal laser scanning microscopy, 3D fluorescence microscopy, electron microscopy and nanoscale secondary ion mass spectrometry, to develop their new approach.
Using this method, they found that bedaquiline had not reached all infected cells in the lung tissue and also had not entered all infected areas within infected cells.
They also found this antibiotic was collecting in macrophages and in polymorphonuclear cells, both types of immune cell. This was a surprise as these cells have different environments and it wasn't thought that one antibiotic would be able to enter both.
Tony Fearns, author and senior laboratory research scientist in the Host-Pathogen Interactions in Tuberculosis Laboratory at the Crick, says: "Our approach could be used to help develop new antibiotics or to re-assess current antibiotics to judge how effectively they reach their targets. The more we learn about how drugs behave in the body, for example where they collect, the better we will be able to treat bacterial diseases like tuberculosis."
Notes to Editors
Fearns, A. et al. (2020) Correlative Light Electron Ion Microscopy reveal in vivo localisation of bedaquiline in Mycobacterium tuberculosis infected lungs. PLoS Biology. DOI
*CLEMiT stands for: Correlative light, electron and ion microscopy in tissue
The Francis Crick Institute is a biomedical discovery institute dedicated to understanding the fundamental biology underlying health and disease. Its work is helping to understand why disease develops and to translate discoveries into new ways to prevent, diagnose and treat illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases.
An independent organisation, its founding partners are the Medical Research Council (MRC), Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King's College London.
The Crick was formed in 2015, and in 2016 it moved into a brand new state-of-the-art building in central London which brings together 1500 scientists and support staff working collaboratively across disciplines, making it the biggest biomedical research facility under a single roof in Europe.